Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(10):655; doi:10.1093/jnci/djj214
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Pak1 Expression and Tamoxifen Resistance

Phosphorylation and activation of estrogen receptor {alpha} (ER{alpha}) by p21-activated kinase 1 (Pak1) could limit the effectiveness of antiestrogen treatment in breast cancer. Holm et al. (p. 671) evaluated Pak1 protein expression and subcellular localization in primary breast tumors from premenopausal patients who had been randomly assigned to receive 2 years of adjuvant tamoxifen or no treatment and compared tamoxifen response in relation to Pak1 and ER{alpha} expression. Among patients with ER{alpha}–positive tumors with low Pak1 expression, those treated with tamoxifen had better recurrence-free survival than those who received no treatment; . . . [Full Text of this Article]

Radiation Therapy and Older Patients with Breast Cancer

Lung Cancer Mortality in Never Smokers

Statin Use and Breast Cancer Risk

Recombinant Human Erythropoietins and Cancer Patients

Prostate Cancer Recurrence after Radical Prostatectomy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?